Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
DAWNRAYS PHARMA Obtains NMPA Drug Production Registration Approval for Antidepressant
Recommend 4 Positive 3 Negative 1 |
||||
|
||||
|
DAWNRAYS PHARMA (02348.HK) announced that the Group’s subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd., has obtained the approval for drug production and registration for Trazodone Hydrochloride Tablets 50mg and 100mg from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. This product is suitable for the treatment of depression and is suitable for patients with or without anxiety. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
